A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

LESSONS LEARNED. The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group. The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma. BACKGROUND. The humanized IgG4 monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Benson, Al B., Wainberg, Zev A., Hecht, J. Randolph, Vyushkov, Dmitry, Dong, Hua, Bendell, Johanna, Kudrik, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344644/
https://www.ncbi.nlm.nih.gov/pubmed/28246206
http://dx.doi.org/10.1634/theoncologist.2017-0024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344644/
https://www.ncbi.nlm.nih.gov/pubmed/28246206
http://dx.doi.org/10.1634/theoncologist.2017-0024

Ejemplares similares